Peptide research and investigations
See what lab reports, price lists and buyer records show before you trust a supplier or a claim. Every article lists its sources, dates and limits.
How Reliable Is Grey-Market Tirzepatide?
We reviewed 12,856 public tirzepatide records against the FDA's quality warnings. High reported purity, variable amounts, original COAs and downloadable data.
Read the articleMost read by recorded views
- $178,146of members' money traced on-chain to Coinbase, Binance & OKX The $150,000 rugpull: Eric Ranks, 'Mr. Based,' and the Peptide University fake-vendor machine
- 27 / 31comparable prices followed the exact three-brand ladder ERP, WBS and JKL: Three Names, One Chinese Peptide Supplier?
- 12,209reported retatrutide purity results reviewed through August 15, 2026 Retatrutide Purity Tests: What 12,209 Results Show
Reports and guides
- Data report The Molecule Is Clean. The Dose Is a Coin Flip.A report on third-party certificate results, peptide purity and labeled-dose accuracy.
- Price index What the Grey Market Costs: Price Per MilligramA price-per-milligram analysis of grey-market peptides, with methods and source limitations.
- Guide Lab Testing 101 for the Grey-Market Peptide SceneWhat third-party certificate tests measure, what they cannot prove, and how to read the results.
More articles
October 2026
- How Reliable Is Grey-Market Tirzepatide?We reviewed 12,856 public tirzepatide records against the FDA's quality warnings. High reported purity, variable amounts, original COAs and downloadable data.
- Can GLP‑1s Fight Crime?Could treating addiction with semaglutide mean fewer arrests? How a planned 1,200-person GLP‑1 trial will test the link between substance use and crime.
- Peptide Shop Case Studies: Names, Timelines and OutcomesExplore 89 peptide and research-chemical matters by shop, alias, compound and outcome. See documented business activity, evidence, punishments and unknowns.
- Peptide Lawsuits by Company: FDA Warnings, Penalties and TimelinesFollow peptide lawsuits and FDA warnings by company, with evidence, penalties, timelines and original FDA reports involving purported retatrutide.
- How to Check if a Peptide Vendor Is Legit: Six Checks and What They Cannot ProveCheck whether a peptide vendor is legit in six steps, from its exact domain to tests it did not commission, with dated evidence and the limits of each.
- Lilly Sues LiveWell Peptides Over Retatrutide: What the Complaint Actually SaysWhat Lilly alleges in its LiveWell Peptides retatrutide lawsuit, the eight state-law claims, requested injunction and limits of the complaint.
- Grey-Market Peptide Testing: Our $27.5 Million EstimateWe priced 113,773 public report groups at $27.5M using current lab rates and estimates. Named peptides and proteins account for $22.68M. See the breakdown.
- The Wegovy Pill Absorbs About 1 to 2%. Why Would a BPC‑157 Capsule Do Better?Oral BPC‑157, KPV and GHK‑Cu capsules compared with approved oral peptide drugs: absorption evidence, acetate versus arginate, liposome claims, and what capsule sellers disclose.
- The Peptide Bait and Switch: A Classic Scam and What You Can Do About It14 lab-report records identified tirzepatide instead of retatrutide. See the price gap, reports and checks that can expose a peptide bait and switch.
September 2026
- Subcutaneous Testosterone: Absorption, Needles and Trade-offsWhat clinical studies show about subcutaneous versus intramuscular testosterone: absorption, injection comfort, needle sizes and product-specific limitations.
- Trenbolone and Mental Health: What 237 Men ReportedWhat studies show about trenbolone, mood, aggression and brain health: reported effects in 237 men, the comparison rates and what remains unknown.
- What Nancy Mace's PEPTIDES for Veterans Act Would Actually DoWe reviewed all five pages of H.R. 10212: the VA research deadlines, conditional pilot, unnamed peptides and unresolved details, with original PDF excerpts.
- Anabolic Steroids and the Brain: Mood, Personality and Young AdultsWhat human studies show about anabolic steroids, mood, brain changes and starting young: measured effects, study excerpts and the limits on lasting harm.
- Intranasal Peptides: What Works, What Absorbs, and What Can Irritate Your Nose?Nasal Semax, Selank, BPC‑157, DSIP and PT‑141: human and animal evidence, absorption, nasal irritation, and saline versus bacteriostatic water.
- How to Get a Peptide Tested: Choose the Test, Vials and LabOrder the test that answers your question: identity, amount, endotoxin or sterility. How many vials to send, how to ship, and how to choose a lab.
- How ChatGPT Promoted a Fake Chinese Peptide WebsiteChatGPT promoted a storefront TitrateLab identifies as a QSC impersonation scam, then repeated its warnings about other fakes. See the captured evidence.
- Endotoxins in 2026: What Grey-Market Peptide Reports ShowGrey-market peptide endotoxins in 2026: reported vendor results, the 2025 comparison, what EU per vial means and what research shows about filtering.
- Are Domestic Peptides Safer? What 85,267 Lab Results ShowDomestic peptide sellers' lab reports fail a third as often as overseas suppliers', but sellers chose 89% of the vials. Customer-sent vials fail about as often.
- TitrateLab Batch Finder: A Praetorian Peptides COA Case StudyFind peptide COAs by compound and batch code. See how TitrateLab's Batch Finder connects reports across vendor names, with screenshots from a real investigation.
- Why Did Human Growth Hormone Disappear From Chinese Vendor Catalogs?Chinese HGH vendor withdrawals, examined through original government sources, 2026 export rules, QSC listings, dated lab reports and price evidence.
- Medicare Part D Spending on Ozempic and Mounjaro in 2024Medicare Part D spending was $12.97B for Ozempic and $6.34B for Mounjaro in 2024, before rebates. Compare CMS ranks, Medicaid totals and evidence limits.
- What Is a Domestic “10x” Peptide Reseller?What a domestic “10x” peptide reseller does, how kit and single-vial prices compare, and how batch numbers can help you look past the label.
- Top 5 International Retatrutide Sellers by Testing VolumeCompare five international retatrutide sellers across 677 lab reports: testing volume, recent coverage, identity failures and reliability limits.
- The Hidden Risks of Ordering Peptides in CanadaA 100 mg peptide kit can exceed 90 days of trial supply. What Canada's import rules, package inspections and enforcement powers mean for buyers.
August 2026
- Janoshik and Vanguard Smack Down Chromate: Inside the Peptide Lab War—and Why the Same Batch Gets Different ResultsJanoshik, Vanguard and Chromate clash over peptide testing methods. Our review found major conflicts in 123 of 179 matched batch-code groups.
- ERP, WBS and JKL: Three Names, One Chinese Peptide Supplier?Why do ERP, WBS and JKL look connected? Shared ads, codes and pricing point to one supply network and reputation insulation across three public names.
- Retatrutide Purity Tests: What 12,209 Results ShowTitrateLab's retatrutide COA analysis covers 12,209 reported purity results: 96.0% were 99–100%, while 164 amount results measured 0 mg. See the limits.
- The Worst Peptide Vendors in 2026, According to Independent Lab TestsFive peptide vendors with the worst documented identity and underfill records in TitrateLab's current independent testing data.
- Peptide COA: How to Read and Verify a Certificate of AnalysisA peptide COA covers one tested sample, not your vial. Verify and read a peptide COA in five checks: lab record, report number, batch, date and test scope.
- A Study Said Up to 71% of Grey-Market Peptides Failed. We Checked 64,787 Lab Records.A preprint reported a 41.6%–71.1% failure rate. TitrateLab reproduced the math, then separated wrong identity, low purity, underfill and overfill across 64,787 checkable lab records.
- Peptaura promised a race to the bottom on price. What it delivered was a race to the bottom on quality.Peptaura brands its own peptides, arranges their laboratory testing, publishes the certificates and marks them verified. Across 112 independent certificates for its flagship Lumira/Welon line, 20 came back as the wrong compound entirely. Newer records show both sides of its response: another identity failure in August, and a separate failed group test that Peptaura did recall.
- QSC Tracy Review: Strong Lab Results, Serious Trust ProblemsA data-driven review of QSC and its sales persona Tracy: strong independent lab results, review-linked pricing, customer disputes, and a MESO-Rx ban.
July 2026
- The $150,000 rugpull: Eric Ranks, 'Mr. Based,' and the Peptide University fake-vendor machineThe Peptide University group-buy "rugpull," explained: how "Mr. Based," Eric Ranks, and the vendors "Bella" and RX Anabolics took roughly $150,000 from members — with the crypto traced on-chain to Coinbase, Binance and OKX. The same grey-market playbook, run at least twice: stand up a vendor nobody can verify, vouch it into trust, funnel members' money, then blame the vendor.
- The July 2026 PCAC peptide vote: FDA proposed no on all seven, and its advisers backed sixFDA proposed keeping seven peptides off the 503A Bulks List. Its advisers backed six on July 23‑24, 2026. As of Oct. 1, 2026, none is on the list.
June 2026
- GLP‑1s and Hair Loss: One Real Signal, One Shaky One, and the Users Who Never Show Up in the DataA pharmacovigilance study of six GLP‑1 drugs found hair loss reported 23 percent more often, and PCOS 6.6 times more often, for semaglutide in the FDA adverse-event database. We read the actual paper: why the hair-loss signal most likely tracks rapid weight loss, why the reproductive number is loud but probably confounded, why the study found the other GLP‑1s quieter rather than identical, and why grey-market self-sourcers are invisible to the whole system.
- Retatrutide Reseller Premiums: What Does the Extra Money Buy?What a retatrutide reseller premium buys: dated kit and single-vial asking prices from ERP, WBS, QSC, Uther, Crush and other storefronts, matched by pack size.
- Over-filled, or short-changed? What 15,167 COAs say about grey-market peptide dosingAre grey-market peptides correctly dosed? Pooled across lab sources, more results run over the label than under it in all 12 compounds we checked; Finnrick's results alone split close to even. Correction, October 1, 2026: retatrutide is 51.1% within 10% of label pooled (45.4% without Finnrick), not the 67% of a June 27 snapshot.
- Peptides for Aging Bones and Joints: What's Proven, What's HypeCan peptides heal aging bones and joints? Every candidate mapped by evidence tier: bone-building is proven FDA medicine, while the joint, tendon, and cartilage claims are strong in animals but unproven in humans.
- Pharma's Quality Bar Is Lower Than You Think. We Measured 62,079 Grey-Market Peptide Tests Against It."Pharmaceutical grade" is the grey market's favorite phrase. We read the rules pharma actually follows, the real USP and FDA limits, and they are looser than most buyers assume: a compliant drug can be 10% off its label, and 95% purity can pass for a peptide. Then we measured 62,079 grey-market peptide certificates against those exact bars. As of July 2026 the dose bar is met by a bare majority, 51.3%. The purity number is a decoy. The endotoxin gap is the one that should change how you buy.
- Does DSIP Actually Work? An Honest Evidence ReviewDoes DSIP actually work? The honest evidence read: tiny old studies (n=6‑16), the best-controlled trial weak-to-negative, no receptor or gene in 49 years, and no modern RCTs. Research-use-only.
- XTP Sold a Retatrutide That Tested as Tirzepatide, Then Said No Test Ever Showed ItBetween late May and July 2026, independent lab tests on products from XTP (known in channels as Xi'an Taiye Chemical Co.) found a multi-product quality collapse on batch XTP-R30‑003. The decisive test was XTP's own: a re-test it paid for, under a tamper-seal protocol it wrote, on three randomly drawn vials, returned about 2mg of tirzepatide in a product sold as 30mg retatrutide. The next day XTP announced that no test had ever shown tirzepatide. This is a dated, source-linked account of what the certificates show.
- CJC‑1295 fails purity more often than any other widely tested peptide in the lab reports we track: 6.25% below 90%, vs 0.21% for tirzepatideMeasured October 1, 2026: 60 of 960 CJC‑1295 lab reports with a purity result (6.25%) tested below 90%, the highest rate of any peptide with 300 or more reports, against 0.21% for tirzepatide and 0.31% for retatrutide. All 60 failures are Finnrick records, and 54 were tested in 2025. Each vendor finding links its certificate.
April 2026
No article matches that.
Follow new research
RSS feedThe LedgerAdd TitrateLab as a preferred source in Google
Have a lab report we don’t?
Submit a certificate. No account needed.
